Biocompatibility and biotolerability assessment of microspheres using a whole blood model

Micro and Nanosystems

Volumn 5, Issue 3, 2013, Pages 177-185

  Rokstad, Anne Mari ^a,d   Strand, Berit ^a,d   Espevik, Terje ^a   Mollnes, Tom Eirik ^b,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d The Central Norway Regional Health Authority ^*  (Norway)

Author keywords

Alginate; Biocompatibility; Biomaterial; Inflammation; Microbead; Microcapsule; Whole blood

Indexed keywords

CELL SURFACE RECEPTORS; CELL TRANSPLANTATION; IDENTICAL CONDITIONS; INFLAMMATION; INFLAMMATORY REACTION; MICROBEADS; MICROCAPSULES; WHOLE BLOOD;

ALGINATE; BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; BIOMATERIALS; COAGULATION; MICROSPHERES;

BLOOD;

EID: 84892988258     PISSN: 18764029     EISSN: 18764037     Source Type: Journal    
DOI: 10.2174/1876402911305030005     Document Type: Review

References (117)

1. Qi, M.; Morch, Y.; Lacik, I.; Formo, K.; Marchese, E.; Wang, Y.; Danielson, K. K.; Kinzer, K.; Wang, S.; Barbaro, B.; Kollarikova, G.; Chorvat, D., Jr.; Hunkeler, D.; Skjak-Braek, G.; Oberholzer, J.; Strand, B. L. Survival of human islets in microbeads containing high guluronic acid alginate crosslinked with Ca(2+) and Ba(2+). Xenotransplantation, 2012, 19(6), 355-364.
2. Omer, A.; Duvivier-Kali, V. F.; Trivedi, N.; Wilmot, K.; Bonner-Weir, S.; Weir, G. C. Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice. Diabetes, 2003, 52(1), 69-75.
3. Lanza, R. P.; Kuhtreiber, W. M.; Ecker, D.; Staruk, J. E.; Chick, W. L. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation, 1995, 59(10), 1377-1384.
4. Duvivier-Kali, V. F.; Omer, A.; Parent, R. J.; O'Neil, J. J.; Weir, G. C. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes, 2001, 50(8), 1698-1705.
5. Dufrane, D.; Goebbels, R. M.; Saliez, A.; Guiot, Y.; Gianello, P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation, 2006, 81(9), 1345-1353.
6. Soon-Shiong, P.; Feldman, E.; Nelson, R.; Komtebedde, J.; Smidsrod, O.; Skjak-Braek, G.; Espevik, T.; Heintz, R.; Lee, M. Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation, 1992, 54(5), 769-774.
7. Soon-Shiong, P.; Feldman, E.; Nelson, R.; Heintz, R.; Yao, Q.; Yao, Z.; Zheng, T.; Merideth, N.; Skjak-Braek, G.; Espevik, T. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(12), 5843-5847.
8. Calafiore, R.; Basta, G.; Luca, G.; Lemmi, A.; Montanucci, M. P.; Calabrese, G.; Racanicchi, L.; Mancuso, F.; Brunetti, P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care, 2006, 29(1), 137-138.
9. Soon-Shiong, P. Treatment of type I diabetes using encapsulated islets. Adv. Drug Deliv. Rev., 1999, 35(2-3), 259-270.
10. Tuch, B. E.; Keogh, G. W.; Williams, L. J.; Wu, W.; Foster, J. L.; Vaithilingam, V.; Philips, R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care, 2009, 32(10), 1887-1889.
11. Li, M.; Carpio, D. F.; Zheng, Y.; Bruzzo, P.; Singh, V.; Ouaaz, F.; Medzhitov, R. M.; Beg, A. A. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol., 2001, 166(12), 7128-7135.
12. Siebers, U.; Horcher, A.; Brandhorst, H.; Brandhorst, D.; Hering, B.; Federlin, K.; Bretzel, R. G.; Zekorn, T. Analysis of the cellular reaction towards microencapsulated xenogeneic islets after intraperitoneal transplantation. J. Mol. Med., 1999, 77(1), 215-218.
13. Merani, S.; Toso, C.; Emamaullee, J.; Shapiro, A. M. Optimal implantation site for pancreatic islet transplantation. Br. J. Surg., 2008, 95(12), 1449-1461.
14. King, A.; Sandler, S.; Andersson, A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J Biomed. Mater. Res., 2001, 57(3), 374-383.
15. King, A.; Strand, B.; Rokstad, A. M.; Kulseng, B.; Andersson, A.; Skjak-Braek, G.; Sandler, S. Improvement of the biocompatibility of alginate/poly-L-lysine/alginate microcapsules by the use of epimerized alginate as a coating. J. Biomed. Mater. Res., 2003, 64(3), 533-539.
16. Kulseng, B.; Skjak-Braek, G.; Ryan, L.; Andersson, A.; King, A.; Faxvaag, A.; Espevik, T. Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation, 1999, 67(7), 978-984.
17. Safley, S. A.; Cui, H.; Cauffiel, S.; Tucker-Burden, C.; Weber, C. J. Biocompatibility and immune acceptance of adult porcine islets transplanted intraperitoneally in diabetic NOD mice in calcium alginate poly-L-lysine microcapsules versus barium alginate microcapsules without poly-L-lysine. J. Diabetes Sci. Technol., 2008, 2(5), 760-767.
18. Strand, B. L.; Ryan, T. L.; In't, V. P.; Kulseng, B.; Rokstad, A. M.; Skjak-Brek, G.; Espevik, T. Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant., 2001, 10(3), 263-275.
19. De Vos, P.; De Haan, B.; van Schilfgaarde, R. Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials, 1997, 18(3), 273-278.
20. Vandenbossche, G. M.; Bracke, M. E.; Cuvelier, C. A.; Bortier, H. E.; Mareel, M. M.; Remon, J. P. Host reaction against empty alginatepolylysine microcapsules. Influence of preparation procedure. J. Pharm. Pharmacol., 1993, 45(2), 115-120.
21. Morch, Y. A.; Donati, I.; Strand, B. L.; Skjak-Braek, G. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. Biomacromolecules, 2006, 7(5), 1471-1480.
22. Strand, B. L.; Morch, Y. A.; Syvertsen, K. R.; Espevik, T.; Skjak-Braek, G. Microcapsules made by enzymatically tailored alginate. J. Biomed. Mater. Res. A., 2003, 64(3), 540-550.
23. Calafiore, R.; Basta, G.; Sarchielli, P.; Luca, G.; Tortoioli, C.; Brunetti, P. A rapid qualitative method to assess in vitro immunobarrier competence of pancreatic islets containing alginate/polyaminoacidic microcapsules. Acta Diabetol., 1996, 33(2), 150-153.
24. Darrabie, M. D.; Kendall, W. F., Jr.; Opara, E. C. Characteristics of Poly-L-Ornithine-coated alginate microcapsules. Biomaterials, 2005, 26(34), 6846-6852.
25. Gaserod, O.; Sannes, A.; Skjak-Braek, G. Microcapsules of alginate-chitosan. II. A study of capsule stability and permeability. Biomaterials, 1999, 20(8), 773-783.
26. Lacik, I.; Brissova, M.; Anilkumar, A. V.; Powers, A. C.; Wang, T. New capsule with tailored properties for the encapsulation of living cells. J. Biomed. Mater. Res., 1998, 39 (1), 52-60.
27. Thu, B.; Bruheim, P.; Espevik, T.; Smidsrod, O.; Soon-Shiong, P.; Skjak-Braek, G. Alginate polycation microcapsules. II. Some functional properties. Biomaterials, 1996, 17(11), 1069-1079.
28. Thu, B.; Bruheim, P.; Espevik, T.; Smidsrod, O.; Soon-Shiong, P.; Skjak-Braek, G. Alginate polycation microcapsules. I. Interaction between alginate and polycation. Biomaterials, 1996, 17(10), 1031-1040.
29. Kulseng, B.; Thu, B.; Espevik, T.; Skjak-Braek, G. Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant., 1997, 6(4), 387-394.
30. Rokstad, A. M.; Holtan, S.; Strand, B.; Steinkjer, B.; Ryan, L.; Kulseng, B.; Skjak-Braek, G.; Espevik, T. Microencapsulation of cells producing therapeutic proteins: optimizing cell growth and secretion. Cell Transplant., 2002, 11(4), 313-324.
31. Rokstad, A. M.; Donati, I.; Borgogna, M.; Oberholzer, J.; Strand, B. L.; Espevik, T.; Skjak-Braek, G. Cell-compatible covalently reinforced beads obtained from a chemoenzymatically engineered alginate. Biomaterials, 2006, 27(27), 4726-4737.
32. Rokstad, A. M.; Brekke, O. L.; Steinkjer, B.; Ryan, L.; Kollarikova, G.; Strand, B. L.; Skjak-Braek, G.; Lacik, I.; Espevik, T.; Mollnes, T. E. Alginate microbeads are complement compatible, in contrast to polycation containing microcapsules, as revealed in a human whole blood model. Acta Biomater., 2011, 7(6), 2566-2578.
33. Shaldon, S. Future trends in biocompatibility aspects of hemodialysis and related therapies. Clin. Nephrol., 1986, 26 Suppl 1, S13-S16.
34. Hakim, R. M. Clinical sequelae of complement activation in hemodialysis. Clin. Nephrol., 1986, 26 Suppl 1, S9-12.
35. Williams, D. F. Definitions in biomaterials. In Progress in biomedical engineering, Amsterdam: Elsevier: 1987.
36. Williams, D. F. On the mechanisms of biocompatibility. Biomaterials, 2008, 29(20), 2941-2953.
37. Ratner, B. D. The biocompatibility manifesto: biocompatibility for the twenty-first century. J. Cardiovasc. Transl. Res., 2011, 4(5), 523-527.
38. Mollnes, T. E. Complement and biocompatibility. Vox Sang., 1998, 74 Suppl 2, 303-307.
39. Klos, A.; Tenner, A. J.; Johswich, K. O.; Ager, R. R.; Reis, E. S.; Kohl, J. The role of the anaphylatoxins in health and disease. Mol. Immunol., 2009, 46(14), 2753-2766.
40. Guo, R. F.; Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol., 2005, 23, 821-852.
41. Rao, L. V.; Pendurthi, U. R. Regulation of tissue factor coagulant activity on cell surfaces. J. Thromb. Haemost., 2012, 10(11), 2242-2253.
42. Osterud, B.; Bjorklid, E. Sources of tissue factor. Semin. Thromb. Hemost., 2006, 32(1), 11-23.
43. Osterud, B. Tissue factor expression in blood cells. Thromb. Res., 2010, 125 Suppl 1, S31-S34.
44. Engstad, C. S.; Lia, K.; Rekdal, O.; Olsen, J. O.; Osterud, B. A novel biological effect of platelet factor 4 (PF4): enhancement of LPSinduced tissue factor activity in monocytes. J. Leukoc. Biol., 1995, 58(5), 575-581.
45. Brekke, O. L.; Waage, C.; Christiansen, D.; Fure, H.; Qu, H.; Lambris, J. D.; Osterud, B.; Nielsen, E. W.; Mollnes, T. E. The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood. Adv. Exp. Med. Biol., 2013, 734, 123-136.
46. Lechner, D.; Weltermann, A. Circulating tissue factor-exposing microparticles. Thromb. Res., 2008, 122 Suppl 1, S47-S54.
47. Oikonomopoulou, K.; Ricklin, D.; Ward, P. A.; Lambris, J. D. Interactions between coagulation and complement--their role in inflammation. Semin. Immunopathol., 2012, 34(1), 151-165.
48. Markiewski, M. M.; Nilsson, B.; Ekdahl, K. N.; Mollnes, T. E.; Lambris, J. D. Complement and coagulation: strangers or partners in crime? Trends Immunol., 2007, 28(4), 184-192.
49. Huber-Lang, M.; Sarma, J. V.; Zetoune, F. S.; Rittirsch, D.; Neff, T. A.; McGuire, S. R.; Lambris, J. D.; Warner, R. L.; Flierl, M. A.; Hoesel, L. M.; Gebhard, F.; Younger, J. G.; Drouin, S. M.; Wetsel, R. A.; Ward, P. A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med., 2006, 12(6), 682-687.
50. Amara, U.; Rittirsch, D.; Flierl, M.; Bruckner, U.; Klos, A.; Gebhard, F.; Lambris, J. D.; Huber-Lang, M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol., 2008, 632, 71-79.
51. Amara, U.; Flierl, M. A.; Rittirsch, D.; Klos, A.; Chen, H.; Acker, B.; Bruckner, U. B.; Nilsson, B.; Gebhard, F.; Lambris, J. D.; Huber-Lang, M. Molecular intercommunication between the complement and coagulation systems. J. Immunol., 2010, 185(9), 5628-5636.
52. Ma, L.; Dorling, A. The roles of thrombin and protease-activated receptors in inflammation. Semin. Immunopathol., 2012, 34(1), 63-72.
53. Kaplanski, G.; Marin, V.; Fabrigoule, M.; Boulay, V.; Benoliel, A. M.; Bongrand, P.; Kaplanski, S.; Farnarier, C. Thrombinactivated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood, 1998, 92(4), 1259-1267.
54. Szaba, F. M.; Smiley, S. T. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood, 2002, 99(3), 1053-1059.
55. Ekdahl, K. N.; Elgue, G.; Nilsson, B. Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin. Thromb. Haemost., 1999, 82(4), 1283-1288.
56. Back, J.; Sanchez, J.; Elgue, G.; Ekdahl, K. N.; Nilsson, B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem. Biophys. Res. Commun., 2010, 391(1), 11-17.
57. Projahn, D.; Koenen, R. R. Platelets: key players in vascular inflammation. J. Leukoc. Biol., 2012, 92(6), 1167-1175.
58. Semple, J. W.; Italiano, J. E., Jr.; Freedman, J. Platelets and the immune continuum. Nat. Rev. Immunol., 2011, 11(4), 264-274.
59. Syrovets, T.; Lunov, O.; Simmet, T. Plasmin as a proinflammatory cell activator. J. Leukoc. Biol., 2012, 92(3), 509-519.
60. Lee, C. C.; Avalos, A. M.; Ploegh, H. L. Accessory molecules for Toll-like receptors and their function. Nat. Rev. Immunol., 2012, 12(3), 168-179.
61. Zhang, X.; Kimura, Y.; Fang, C.; Zhou, L.; Sfyroera, G.; Lambris, J. D.; Wetsel, R. A.; Miwa, T.; Song, W. C. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood, 2007, 110(1), 228-236.
62. Wang, M.; Krauss, J. L.; Domon, H.; Hosur, K. B.; Liang, S.; Magotti, P.; Triantafilou, M.; Triantafilou, K.; Lambris, J. D.; Hajishengallis, G. Microbial hijacking of complement-toll-like receptor crosstalk. Sci. Signal., 2010, 3(109), ra11.
63. Hamad, O. A.; Ekdahl, K. N.; Nilsson, P. H.; Andersson, J.; Magotti, P.; Lambris, J. D.; Nilsson, B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J. Thromb. Haemost., 2008, 6(8), 1413-1421.
64. Hajishengallis, G.; Lambris, J. D. Complement and dysbiosis in periodontal disease. Immunobiology, 2012, 217(11), 1111-1116.
65. Happonen, K. E.; Heinegard, D.; Saxne, T.; Blom, A. M. Interactions of the complement system with molecules of extracellular matrix: Relevance for joint diseases. Immunobiology, 2012, 217(11), 1088-1096.
66. Karsten, C. M.; Kohl, J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology, 2012, 217 (11), 1067-1079.
67. Rittirsch, D.; Flierl, M. A.; Ward, P. A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol., 2008, 8(10), 776-787.
68. Barratt-Due, A.; Pischke, S. E.; Brekke, O. L.; Thorgersen, E. B.; Nielsen, E. W.; Espevik, T.; Huber-Lang, M.; Mollnes, T. E. Bride and groom in systemic inflammation-The bells ring for complement and Toll in cooperation. Immunobiology, 2012, 217(11), 1047-1056.
69. Hajishengallis, G.; Lambris, J. D. Crosstalk pathways between Tolllike receptors and the complement system. Trends Immunol., 2010, 31(4), 154-163.
70. Nilsson, B.; Korsgren, O.; Lambris, J. D.; Ekdahl, K. N. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol., 2010, 31(1), 32-38.
71. Engstad, C. S.; Gutteberg, T. J.; Osterud, B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb. Haemost., 1997, 77(4), 690-696.
72. Mollnes, T. E.; Brekke, O. L.; Fung, M.; Fure, H.; Christiansen, D.; Bergseth, G.; Videm, V.; Lappegard, K. T.; Kohl, J.; Lambris, J. D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin based human whole blood model of inflammation. Blood, 2002, 100(5), 1869-1877.
73. Harboe, M.; Thorgersen, E. B.; Mollnes, T. E. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev., 2011, 63(12), 976-987.
74. Stalker, T. J.; Newman, D. K.; Ma, P.; Wannemacher, K. M.; Brass, L. F. Platelet signaling. Handb. Exp. Pharmacol., 2012, (210), 59-85.
75. Coppinger, J. A.; O'Connor, R.; Wynne, K.; Flanagan, M.; Sullivan, M.; Maguire, P. B.; Fitzgerald, D. J.; Cagney, G. Moderation of the platelet releasate response by aspirin. Blood, 2007, 109(11), 4786-4792.
76. Rabiet, M. J.; Blashill, A.; Furie, B.; Furie, B. C. Prothrombin fragment 1 X 2 X 3, a major product of prothrombin activation in human plasma. J. Biol. Chem., 1986, 261(28), 13210-13215.
77. Bexborn, F.; Engberg, A. E.; Sandholm, K.; Mollnes, T. E.; Hong, J.; Nilsson, E. K. Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J. Biomed. Mater. Res. A., 2009, 89(4), 951-959.
78. Bar-Shavit, R.; Kahn, A.; Fenton, J. W.; Wilner, G. D. Chemotactic response of monocytes to thrombin. J. Cell Biol., 1983, 96(1), 282-285.
79. Johnson, K.; Aarden, L.; Choi, Y.; De, G. E.; Creasey, A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood, 1996, 87(12), 5051-5060.
80. Kranzhofer, R.; Clinton, S. K.; Ishii, K.; Coughlin, S. R.; Fenton, J. W.; Libby, P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ. Res., 1996, 79(2), 286-294.
81. Olsson, P.; Sanchez, J.; Mollnes, T. E.; Riesenfeld, J. On the blood compatibility of end-point immobilized heparin. J. Biomater. Sci. Polym. Ed., 2000, 11(11), 1261-1273.
82. Andersson, J.; Sanchez, J.; Ekdahl, K. N.; Elgue, G.; Nilsson, B.; Larsson, R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human nonanticoagulated blood in vitro. J. Biomed. Mater. Res. A., 2003, 67(2), 458-466.
83. Bennet, W.; Sundberg, B.; Lundgren, T.; Tibell, A.; Groth, C. G.; Richards, A.; White, D. J.; Elgue, G.; Larsson, R.; Nilsson, B.; Korsgren, O. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation, 2000, 69(5), 711-719.
84. Bennet, W.; Sundberg, B.; Groth, C. G.; Brendel, M. D.; Brandhorst, D.; Brandhorst, H.; Bretzel, R. G.; Elgue, G.; Larsson, R.; Nilsson, B.; Korsgren, O. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes, 1999, 48(10), 1907-1914.
85. Gong, J.; Larsson, R.; Ekdahl, K. N.; Mollnes, T. E.; Nilsson, U.; Nilsson, B. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J. Clin. Immunol., 1996, 16(4), 222-229.
86. Pekna, M.; Larsson, R.; Formgren, B.; Nilsson, U. R.; Nilsson, B. Complement activation by polymethyl methacrylate minimized by end-point heparin attachment. Biomaterials, 1993, 14(3), 189-192.
87. Brekke, O. L.; Christiansen, D.; Fure, H.; Fung, M.; Mollnes, T. E. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol., 2007, 81(6), 1404-1413.
88. Christiansen, D.; Brekke, O. L.; Stenvik, J.; Lambris, J. D.; Espevik, T.; Mollnes, T. E. Differential effect of inhibiting MD-2 and CD14 on LPS-versus whole E. coli bacteria-induced cytokine responses in human blood. Adv. Exp. Med. Biol., 2012, 946, 237-251.
89. Lappegard, K. T.; Christiansen, D.; Pharo, A.; Thorgersen, E. B.; Hellerud, B. C.; Lindstad, J.; Nielsen, E. W.; Bergseth, G.; Fadnes, D.; Abrahamsen, T. G.; Hoiby, E. A.; Schejbel, L.; Garred, P.; Lambris, J. D.; Harboe, M.; Mollnes, T. E. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(37), 15861-15866.
90. Thorgersen, E. B.; Pharo, A.; Haverson, K.; Axelsen, A. K.; Gaustad, P.; Kotwal, G. J.; Sfyroera, G.; Mollnes, T. E. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect. Immun., 2009, 77(2), 725-732.
91. Brekke, O. L.; Christiansen, D.; Fure, H.; Pharo, A.; Fung, M.; Riesenfeld, J.; Mollnes, T. E. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine-and growth factor-synthesis in human whole blood. Mol. Immunol., 2008, 45(14), 3804-3813.
92. Lappegard, K. T.; Bergseth, G.; Riesenfeld, J.; Sexton, J.; Mollnes, T. E. Role of granulocytes and monocytes in the polyvinyl chlorideinduced synthesis of interleukin 8, monocyte chemoattractant protein 1, and leukotriene B4. J. Biomed. Mater. Res. A., 2005, 74(2), 230-236.
93. Lappegard, K. T.; Bergseth, G.; Riesenfeld, J.; Pharo, A.; Magotti, P.; Lambris, J. D.; Mollnes, T. E. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J. Biomed. Mater. Res. A., 2008, 87(1), 129-135.
94. Lappegard, K. T.; Fung, M.; Bergseth, G.; Riesenfeld, J.; Mollnes, T. E. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition. Ann. Thorac. Surg., 2004, 78(1), 38-44.
95. Sokolov, A.; Hellerud, B. C.; Pharo, A.; Johannessen, E. A.; Mollnes, T. E. Complement activation by candidate biomaterials of an implantable microfabricated medical device. J. Biomed. Mater. Res. B Appl. Biomater., 2011, 98B(2), 323-329.
96. Sokolov, A.; Hellerud, B. C.; Johannessen, E. A.; Mollnes, T. E. Inflammatory response induced by candidate biomaterials of an implantable microfabricated sensor. J. Biomed. Mater. Res. A., 2012, 100(5), 1142-1150.
97. Bergseth, G.; Lambris, J. D.; Mollnes, T. E.; Lappegard, K. T. Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person. Ann. Thorac. Surg., 2011, 91(2), 527-533.
98. Rokstad, A. M.; Brekke, O. L.; Steinkjer, B.; Ryan, L.; Kollarikova, G.; Strand, B. L.; Skjak-Braek, G.; Lambris, J. D.; Lacik, I.; Mollnes, T. E.; Espevik, T. The induction of cytokines by polycation containing microspheres by a complement dependent mechanism. Biomaterials, 2013, 34(3), 621-30.
99. Nilsson, U. R.; Larm, O.; Nilsson, B.; Storm, K. E.; Elwing, H.; Nilsson, E. K. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand. J. Immunol., 1993, 37(3), 349-354.
100. Harboe, M.; Ulvund, G.; Vien, L.; Fung, M.; Mollnes, T. E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol., 2004, 138 (3), 439-446.
101. Harboe, M.; Garred, P.; Borgen, M. S.; Stahl, G. L.; Roos, A.; Mollnes, T. E. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin. Exp. Immunol., 2006, 144(3), 512-520.
102. Andersson, J.; Ekdahl, K. N.; Lambris, J. D.; Nilsson, B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials, 2005, 26(13), 1477-1485.
103. Gros, P.; Milder, F. J.; Janssen, B. J. Complement driven by conformational changes. Nat. Rev. Immunol., 2008, 8(1), 48-58.
104. Mollnes, T. E.; Riesenfeld, J.; Garred, P.; Nordstrom, E.; Hogasen, K.; Fosse, E.; Gotze, O.; Harboe, M. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs, 1995, 19(9), 909-917.
105. Eisen, V.; Loveday, C. In vivo effects of cellulose sulphate on plasma kininogen, complement and inflammation. Br. J. Pharmacol., 1971, 42(3), 383-391.
106. Boor, P.; Konieczny, A.; Villa, L.; Schult, A. L.; Bucher, E.; Rong, S.; Kunter, U.; van Roeyen, C. R.; Polakowski, T.; Hawlisch, H.; Hillebrandt, S.; Lammert, F.; Eitner, F.; Floege, J.; Ostendorf, T. Complement C5 mediates experimental tubulointerstitial fibrosis. J. Am. Soc. Nephrol., 2007, 18(5), 1508-1515.
107. Akalin, H. E.; Fisher, K. A.; Laleli, Y.; Caglar, S. Bactericidal activity of ascitic fluid in patients with nephrotic syndrome. Eur. J. Clin. Invest., 1985, 15(3), 138-140.
108. De Haan, B. J.; Rossi, A.; Faas, M. M.; Smelt, M. J.; Sonvico, F.; Colombo, P.; de, V. P. Structural surface changes and inflammatory responses against alginate-based microcapsules after exposure to human peritoneal fluid. J. Biomed. Mater. Res. A., 2011, 98(3), 394-403.
109. Kvarnstrom, A.; Sokolov, A.; Swartling, T.; Kurlberg, G.; Mollnes, T. E.; Bengtsson, A. Alternative pathway activation of complement in laparoscopic and open rectal surgery. Scand. J. Immunol., 2012, 76(1), 49-53.
110. Boeuf, S.; Klingenspor, M.; Van Hal, N. L.; Schneider, T.; Keijer, J.; Klaus, S. Differential gene expression in white and brown preadipocytes. Physiol Genomics, 2001, 7(1), 15-25.
111. Pattrick, M.; Luckett, J.; Yue, L.; Stover, C. Dual role of complement in adipose tissue. Mol. Immunol., 2009, 46(5), 755-760.
112. Tilg, H.; Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol., 2006, 6(10), 772-783.
113. Kopp, A.; Buechler, C.; Neumeier, M.; Weigert, J.; Aslanidis, C.; Scholmerich, J.; Schaffler, A. Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity. (Silver. Spring), 2009, 17(4), 648-656.
114. Le, Y.; Zhou, Y.; Iribarren, P.; Wang, J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol. Immunol., 2004, 1(2), 95-104.
115. Koch, AE.; Polverini, P. J.; Kunkel, S. L.; Harlow, L. A.; Dipietro, L. A.; Elner, V. M.; Elner, S. G.; Strieter, R. M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 1992, 258(5089), 1798-1801.
116. Belperio, J. A.; Keane, M. P.; Burdick, M. D.; Gomperts, B.; Xue, Y. Y.; Hong, K.; Mestas, J.; Ardehali, A.; Mehrad, B.; Saggar, R.; Lynch, J. P.; Ross, D. J.; Strieter, R. M. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J. Clin. Invest., 2005, 115(5), 1150-1162.
117. Qi, M.; Lacik, I.; Kollarikova, G.; Strand, B. L.; Formo, K.; Wang, Y.; Marchese, E.; Mendoza-Elias, J. E.; Kinzer, K. P.; Gatti, F.; Paushter, D.; Patel, S.; Oberholzer, J. A recommended laparoscopic procedure for implantation of microcapsules in the peritoneal cavity of non-human primates. J. Surg. Res., 2011, 168(1), e117-e123.